NASDAQ:AKTX

Akari Therapeutics - AKTX Stock Forecast, Price & News

$1.42

-0.04 (-2.74%)

(As of 08/18/2022 11:08 AM ET)

Add

Compare

Today's Range: $1.42
▼
$1.42
50-Day Range: $0.83
▼
$1.59
52-Week Range: $0.75
▼
$1.88

Volume: 3 shs
Average Volume: 111,205 shs
Market Capitalization: $84.28 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Akari Therapeutics (NASDAQ:AKTX) Stock

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Akari Therapeutics Stock Performance

AKTX Stock opened at $1.42 on Thursday. The firm has a market cap of $84.28 million, a price-to-earnings ratio of -3.94 and a beta of 1.28. The firm has a 50-day simple moving average of $1.08 and a two-hundred day simple moving average of $1.16. Akari Therapeutics has a one year low of $0.75 and a one year high of $1.88.

Akari Therapeutics (NASDAQ:AKTX - Get Rating) last issued its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.12) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Akari Therapeutics in a research note on Wednesday. They issued a "sell" rating on the stock.

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Stock News Headlines

August 11, 2022 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated at StockNews.com

August 10, 2022 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.com

August 18, 2022 | Investing Trends (Ad)

Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium

The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.

August 2, 2022 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Narrows Pipeline Focus

August 1, 2022 | finance.yahoo.com

Akari Therapeutics Narrows Pipeline Focus

July 29, 2022 | finance.yahoo.com

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

July 28, 2022 | finance.yahoo.com

Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

July 20, 2022 | finance.yahoo.com

Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

August 18, 2022 | Investing Trends (Ad)

Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium

July 7, 2022 | finance.yahoo.com

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

June 13, 2022 | seekingalpha.com

Akari Therapeutics appoints Melissa Bradford-Klug as COO

May 19, 2022 | finance.yahoo.com

Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting

May 16, 2022 | seekingalpha.com

Akari Therapeutics net loss of $17.4M

May 16, 2022 | finance.yahoo.com

Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress

May 11, 2022 | finance.yahoo.com

Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting

May 10, 2022 | finance.yahoo.com

Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology

May 9, 2022 | finance.yahoo.com

Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)

March 21, 2022 | finance.yahoo.com

Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

March 9, 2022 | finance.yahoo.com

Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch

March 8, 2022 | seekingalpha.com

Akari Therapeutics slips on $9M equity offering

March 8, 2022 | finance.yahoo.com

Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering

March 5, 2022 | finance.yahoo.com

One Akari Therapeutics, Plc (NASDAQ:AKTX) insider upped their stake by 180% in the previous year

March 3, 2022 | marketwatch.com

Akari Therapeutics Names Rachelle Jacques as President, CEO

March 2, 2022 | seekingalpha.com

Akari Therapeutics picks new CEO

March 2, 2022 | finance.yahoo.com

Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

February 28, 2022 | finance.yahoo.com

Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma

February 11, 2022 | finance.yahoo.com

Akari Therapeutics to Present at BIO CEO & Investor Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Company Calendar

Last Earnings: 3/31/2020
Today: 8/18/2022
Next Earnings (Estimated): 9/28/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AKTX
CUSIP: N/A
CIK: 1541157
Web: www.akaritx.com
Phone: 442080040261
Fax: 646-843-9352
Employees: 9
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -206.69%
Return on Assets: -132.36%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.52
Quick Ratio: 3.52

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.11 per share
Price / Book: 12.91

Miscellaneous

Outstanding Shares: 59,350,000
Free Float: 22,671,000
Market Cap: $84.28 million
Optionable: Not Optionable
Beta: 1.28

Key Executives

Dr. Ray Prudo-Chlebosz M.D. (Age 77)
Exec. Chairman
Comp: $618k
Dr. Torsten Hombeck (Age 52)
Chief Financial Officer
Comp: $454.88k
Ms. Rachelle Suzanne Jacques (Age 51)
Pres, CEO & Director
Ms. Melissa Bradford-Klug
Chief Operating Officer
Dr. Miles Nunn
Chief Scientific Officer
Annie Mack
Financial Controller

Key Competitors

View All Competitors

Insiders & Institutions

LPL Financial LLC
Bought 83,334 shares on 8/12/2022
Ownership: 0.140%

View All Insider Transactions
View All Institutional Transactions

AKTX Stock - Frequently Asked Questions

How have AKTX shares performed in 2022?: Akari Therapeutics' stock was trading at $1.50 at the start of the year. Since then, AKTX stock has decreased by 5.3% and is now trading at $1.42.
View the best growth stocks for 2022 here.
When is Akari Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 28th 2022.
View our AKTX earnings forecast.
How were Akari Therapeutics' earnings last quarter?: Akari Therapeutics, Plc (NASDAQ:AKTX) issued its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.25.
What other stocks do shareholders of Akari Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX).

What is Akari Therapeutics' stock symbol?: Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."
Who are Akari Therapeutics' major shareholders?: Akari Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include LPL Financial LLC (0.14%).
View institutional ownership trends.
How do I buy shares of Akari Therapeutics?: Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Akari Therapeutics' stock price today?: One share of AKTX stock can currently be purchased for approximately $1.42.
How much money does Akari Therapeutics make?: Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $84.28 million. The biopharmaceutical company earns $-17,420,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.
How can I contact Akari Therapeutics?: Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352.

This page (NASDAQ:AKTX) was last updated on 8/18/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here